On this page

nystatin

Prescription ANDA TE AA Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
nystatin
Generic name
nystatin
Dosage form
Tablet, Coated
Route
Oral
Marketing category
ANDA · ANDA
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
5
Packages
10
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Nystatin 500000 [USP'U]/1 261178 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Tablet, Coated
Route of administration
Oral
Presentations
15

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Polyene Antifungal [EPC] EPC All 12 members
Polyenes [CS] CS All 13 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
062474
Application type
ANDA · Abbreviated New Drug Application
Approval date
December 22, 1983
Sponsor
HERITAGE
Products on application
1
Submissions recorded
6
Products approved under application 062474.
Product Trade name Form Strength Ingredient Status TE Flags
062474-001 NYSTATIN TABLET NYSTATIN Prescription AA

Therapeutic equivalence

Source: Orange Book
TE code
AA
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — no known or suspected bioequivalence problems (conventional dosage forms)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 062474.
Type No. Action Status Date Review
Supplement 10 Manufacturing (CMC) Approved November 1, 2012 —
Supplement 6 Manufacturing (CMC) Approved October 29, 1997 —
Supplement 9 Labeling Approved July 11, 1997 —
Supplement 8 Manufacturing (CMC) Approved December 15, 1993 —
Supplement 7 Manufacturing (CMC) Approved December 15, 1993 —
Original application 1 Approved December 22, 1983 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260805). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260805

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Nystatin tablets are intended for the treatment of non-esophageal mucus membrane gastrointestinal candidiasis.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION The usual therapeutic dosage is one to two tablets (500,000 to 1,000,000 units nystatin) three times daily. Treatment should generally be continued for at least 48 hours after clinical cure to prevent relapse.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Nystatin tablets are contraindicated in patients with a history of hypersensitivity to any of their components.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See PRECAUTIONS: General . ) Gastrointestinal Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances. Dermatologic Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely. Other Tachycardia, bronchospasm, facial swelling, and nonspecific myalgia have also been rarely reported. To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Description

openFDA Drug Labeling

DESCRIPTION Nystatin is an antimycotic polyene antibiotic obtained from Streptomyces noursei . Its structural formula: C 47 H 75 NO 17 M.W. 926.13 Nystatin tablets are for oral administration and contain 500,000 units of nystatin per tablet. Nystatin tablets contain the inactive ingredients: corn starch, confectioner sugar, dibasic calcium phosphate, FD&C yellow #6, FD&C red #40, FD&C blue # 2, hydroxypropyl cellulose, hypromellose, microcrystalline cellulose, magnesium stearate, polyethylene glycol, polysorbate 80, talc and titanium dioxide. Image

OVERDOSAGE Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (see CLINICAL PHARMACOLOGY, Pharmacokinetics ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Nystatin Tablets USP, 500,000 Units are round brown, film-coated tablets debossed "HP51" on one side and plain on the other side are packaged in: Bottles of 120: NDC 68788-8690-1 Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Manufactured by: Strides Pharma Science Limited Puducherry- 605 014, India. PON/DRUGS/16 13 4193 Distributed by: Avet Pharmaceuticals Inc. East Brunswick, NJ 08816 1.866.901.DRUG (3784) 1041073 Rev: 06/2020 OR Manufactured by: Strides Alathur Private Limited Alathur, Chengalpattu – 603 110, Tamilnadu, India. M.L. No.: TN00002327 Manufactured for: Avet Pharmaceuticals Inc. East Brunswick, NJ 08816 1.866.901.DRUG(3784) 1049633 Revised: 01/2024 Repackaged By: Preferred Pharmaceuticals Inc. logo Avet logo

Adverse event reports

Source: openFDA FAERS
27,387
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: NYSTATIN. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
63629-8350-1 63629-8350 Bryant Ranch Prepack 28 TABLET, COATED in 1 BOTTLE (63629-8350-1) April 29, 2022
63629-8350-2 63629-8350 Bryant Ranch Prepack 56 TABLET, COATED in 1 BOTTLE (63629-8350-2) September 2, 2020
63629-8350-3 63629-8350 Bryant Ranch Prepack 30 TABLET, COATED in 1 BOTTLE (63629-8350-3) September 2, 2020
63629-8350-4 63629-8350 Bryant Ranch Prepack 120 TABLET, COATED in 1 BOTTLE (63629-8350-4) June 7, 2024
23155-051-01 23155-051 Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 100 TABLET, COATED in 1 BOTTLE (23155-051-01) October 31, 2011
68071-3508-9 68071-3508 NuCare Pharmaceuticals,Inc. 90 TABLET, COATED in 1 BOTTLE (68071-3508-9) September 20, 2023
68788-8690-1 68788-8690 Preferred Pharmaceuticals Inc. 120 TABLET, COATED in 1 BOTTLE (68788-8690-1) June 7, 2024
71205-575-30 71205-575 Proficient Rx LP 30 TABLET, COATED in 1 BOTTLE (71205-575-30) June 8, 2021
71205-575-60 71205-575 Proficient Rx LP 60 TABLET, COATED in 1 BOTTLE (71205-575-60) June 8, 2021
71205-575-90 71205-575 Proficient Rx LP 90 TABLET, COATED in 1 BOTTLE (71205-575-90) June 8, 2021
63629-8350 63629-8350 Bryant Ranch Prepack — October 31, 2011
23155-051 23155-051 Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. — October 31, 2011
68071-3508 68071-3508 NuCare Pharmaceuticals,Inc. — October 31, 2011
68788-8690 68788-8690 Preferred Pharmaceuticals Inc. — June 7, 2024
71205-575 71205-575 Proficient Rx LP — October 31, 2011

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.